2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 8, 2017

9:00AM-10:30AM: Abstract Number: 2897

A Non-Coding Genetic Variant Maximally Associated with Serum Urate Levels Is Functionally Linked to HNF4A-Dependent PDZK1 Expression

Metabolic and Crystal Arthropathies II: Mechanisms of Crystal Inflammation and Metabolism

9:00AM-10:30AM: Abstract Number: 2923

A Propensity Score-Matched Study of Organ Damage in Patients with Systemic Lupus Erythematosus from the BLISS Long-Term Extension Trials Versus the Toronto Lupus Cohort: A Post Hoc Longitudinal Analysis

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Longterm Outcomes

9:00AM-10:30AM: Abstract Number: 2914

Anti-CCP Antibody Levels Are Elevated in Cervicovaginal Fluid in Association with Local Inflammation in Premenopausal Women without RA

Rheumatoid Arthritis – Human Etiology and Pathogenesis II

9:00AM-10:30AM: Abstract Number: 2901

Anti-Inflammatory Mechanism of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis in THP-1 Macrophages Is Mediated By NALP3 Inflammasome.

Metabolic and Crystal Arthropathies II: Mechanisms of Crystal Inflammation and Metabolism

9:00AM-10:30AM: Abstract Number: 2936

B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis

Vasculitis III: Pathogenesis

9:00AM-10:30AM: Abstract Number: 2934

Comparative Analysis of the Macrophage Glycolytic Machinery in Giant Cell Arteritis (GCA) and in Coronary Artery Disease (CAD)

Vasculitis III: Pathogenesis

9:00AM-10:30AM: Abstract Number: 2920

Comparative Rates of Osteoporotic Fractures Among U.S. Medicaid Enrollees with and without Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Longterm Outcomes

9:00AM-10:30AM: Abstract Number: 2910

Comparison of Clinical and Ultrasound Measures of Disease Activity in a Large National ‘Real Life’ Cohort of RA Patients

Rheumatoid Arthritis – Clinical Aspects VI: Comorbidities of Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 2992

Curbing the Opioid Epidemic: Predictors of Opioid Use in Juvenile Fibromyalgia Syndrome

ACR/ARHP Combined: Pediatrics

9:00AM-10:30AM: Abstract Number: 2891

Do Certain Dmards Increase Risk of New-Onset Type 2 Diabetes in RA Patients? a Disease Risk Score Analysis Using Administrative Databases

Health Services Research II: Methods and Technology in Care and Research

9:00AM-10:30AM: Abstract Number: 2925

Economic Evaluation of Damage Accrual in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Longterm Outcomes

9:00AM-10:30AM: Abstract Number: 2924

Effect of Antimalarials over the Different Domains of the Damage INDEX in Latin American SLE Patients

Systemic Lupus Erythematosus – Clinical Aspects and Treatment V: Longterm Outcomes

9:00AM-10:30AM: Abstract Number: 2904

Efficacy and Tolerance of TNF Alpha Inhibitor (TNFI) Treatment in Cardiac Sarcoidosis (CS)

Miscellaneous Rheumatic and Inflammatory Diseases II

9:00AM-10:30AM: Abstract Number: 2926

Fucosyltransferase-1 Mediates Macrophage Driven Myofibroblast Differentiation and TGF-β Signaling in Systemic Sclerosis and Bleomycin-Induced Fibrosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

9:00AM-10:30AM: Abstract Number: 2937

Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease

Vasculitis III: Pathogenesis

1
2
3
…
8
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].